Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma

Table 1

Correlations between the occurrence of TD and clinicopathological characteristics.

Variables	Number (%)	TD		P
		Absent	Present
Gender
Female	6 (7.3)	4 (66.7)	2 (33.3)	0.596
Male	76 (92.3)	56 (76.3)	18 (23.7)
Age (years)
≤ 65	53 (64.6)	38 (71.7)	15 (28.3)	0.265
> 65	29 (35.4)	24 (82.8)	5 (17.2)
Performance status
0	15 (18.3)	8 (53.3)	7 (46.7)	0.032
1	51 (62.2)	39 (76.5)	12 (23.5)
2	16 (19.5)	15 (93.8)	1 (6.3)
Smoking status
Never	20 (24.4)	13 (65.0)	7 (35.0)	0.204
Current and former	62 (75.6)	49 (79.0)	13 (21.0)
Alcohol status
Never	19 (23.2)	13 (68.4)	6 (31.6)	0.405
Current and former	63 (76.8)	49 (77.8)	14 (22.2)
Combined with chemotherapy
No	23 (28.0)	16 (69.6)	7 (30.4)	0.426
Yes	59 (72.0)	46 (78.0)	13 (22.0)
Treatment lines
First	25 (30.5)	20 (80.0)	5 (20.0)	0.540
Second or more	57 (69.5)	42 (73.7)	15 (26.3)
Tumor location
Cervical or upper thoracic	11 (13.4)	9 (81.8)	2 (18.2)	0.819
Middle thoracic	42 (51.2)	32 (76.2)	10 (23.8)
Lower thoracic	29 (35.4)	21 (72.4)	8 (27.6)
Previous surgery
No	45 (54.9)	36 (80.0)	9 (20.0)	0.307
Yes	37 (45.1)	26 (70.3)	11 (29.7)
Previous radiotherapy
No	37 (45.1)	33 (89.2)	4 (10.8)	0.009
Yes	45 (54.9)	29 (64.4)	16 (35.6)
Supraclavicular radiotherapy
No	62 (75.6)	48 (77.4)	14 (22.6)	0.502
Yes	20 (24.4)	14 (70.0)	6 (30.0)
Stage
III	8 (9.8)	5 (62.5)	3 (37.5)	0.363
IV	74 (90.2)	57 (77.0)	17 (23.0)
Liver metastasis
No	60 (73.2)	42 (70.0)	18 (30.0)	0.051
Yes	22 (26.8)	20 (90.9)	2 (9.1)